跳至主要内容
临床试验/NL-OMON55153
NL-OMON55153已完成不适用

The influence of CYP2C19 loss-of-function alleles on atherothrombotic events in patients on clopidogrel after endovascular aneurysm repair (EVAR) - GEN-EVAR

Radboud Universitair Medisch Centrum0 个研究点目标入组 300 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • - adult patients (age > 18 years)
  • - obtained written informed consent
  • - patients with the ability to perform a buccal swab at home
  • - patients who were treated for an infrarenal AAA with EVAR between January
  • 2016 and July 2019, including those that were additionally treated with an
  • iliac branched device and/or coiling of the internal iliac artery
  • - patients who are on continues treatment with clopidogrel as single
  • thrombocyte aggregation inhibitor since EVAR

排除标准

  • - patients with a known CYP2C19*2 and *3 status
  • - patients who are treated with other antithrombotic medications (aspirin,
  • ticagrelor, prasugrel, coumarins, Non-vitamin K Oral Anti-Coagulants (NOACs),
  • in combination with clopidogrel
  • - Patient treated for a juxtarenal AAA with Fenestrated-EVAR, Chimney-EVAR or
  • open surgical repair
  • - Patients that have used clopidogral only temporary after EVAR

研究者

相似试验